MTOR and carcinoma: On the one hand, the progression of NET-LM is much slower than in other GEP carcinomas and is well controlled by systemic therapies, such as somatostatin analogues (PROMID, CLARINET [66]), peptide receptor radionuclide therapy (PRRT) with 177-lutetium (NETTER-1 trial [67]) and the mammalian target of rapamycin inhibitor (mTOR) everolimus (RADIANT trials [68]) over a long period of time [67]; on the other hand, recurrence rates after liver transplantation are high, so transplantation as a curative therapy remains questionable.